Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ADALIMUMAB Cause Chronic kidney disease? 809 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 809 reports of Chronic kidney disease have been filed in association with ADALIMUMAB (YUSIMRY). This represents 0.2% of all adverse event reports for ADALIMUMAB.

809
Reports of Chronic kidney disease with ADALIMUMAB
0.2%
of all ADALIMUMAB reports
47
Deaths
257
Hospitalizations

How Dangerous Is Chronic kidney disease From ADALIMUMAB?

Of the 809 reports, 47 (5.8%) resulted in death, 257 (31.8%) required hospitalization, and 8 (1.0%) were considered life-threatening.

Is Chronic kidney disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ADALIMUMAB. However, 809 reports have been filed with the FAERS database.

What Other Side Effects Does ADALIMUMAB Cause?

Drug ineffective (71,926) Pain (37,514) Arthralgia (35,592) Rheumatoid arthritis (29,817) Fatigue (29,420) Injection site pain (28,679) Headache (19,891) Nausea (19,299) Rash (18,690) Pain in extremity (18,319)

What Other Drugs Cause Chronic kidney disease?

OMEPRAZOLE (35,759) ESOMEPRAZOLE (35,281) LANSOPRAZOLE (32,517) PANTOPRAZOLE (28,127) DEXLANSOPRAZOLE (15,973) EMTRICITABINE\TENOFOVIR DISOPROXIL (10,248) TENOFOVIR DISOPROXIL (7,230) EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL (5,861) RABEPRAZOLE (4,773) ESOMEPRAZOLE\NAPROXEN (2,714)

Which ADALIMUMAB Alternatives Have Lower Chronic kidney disease Risk?

ADALIMUMAB vs ADALIMUMAB-AACF ADALIMUMAB vs ADALIMUMAB-AATY ADALIMUMAB vs ADALIMUMAB-ADAZ ADALIMUMAB vs ADALIMUMAB-ADBM ADALIMUMAB vs ADALIMUMAB-AFZB

Related Pages

ADALIMUMAB Full Profile All Chronic kidney disease Reports All Drugs Causing Chronic kidney disease ADALIMUMAB Demographics